Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix announced the dosing of the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating JNJ-1900 (NBTXR3) for treating Stage 3 unresectable non-small cell lung cancer. The study will assess patients receiving standard chemoradiation followed by consolidation durvalumab.

The trial (NCT06667908) is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. JNJ-1900 is a potential first-in-class radioenhancer designed to address unmet needs in radiotherapy patients. This development follows the NANORAY-312 trial path for potential registration in head and neck cancer.

Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.

Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.

The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.

Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of November 30, 2024. The company has 47,426,851 shares outstanding, with 49,202,229 theoretical voting rights and 49,180,111 exercisable voting rights. Nanobiotix, founded in 2003 and headquartered in Paris, is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients. The study showed encouraging results with 23 months median Overall Survival from diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson.

The treatment was well-tolerated, and investigators concluded the favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial. The FDA approved a protocol amendment to launch a new cohort studying NBTXR3 combined with standard-of-care concurrent chemotherapy, with recruitment currently ongoing. Full data presentation is expected at a medical congress in first half of 2025.

Nanobiotix has released its monthly report on voting rights and share capital as of October 31, 2024. The company reported 47,426,851 shares outstanding, with 49,201,086 theoretical voting rights and 49,178,968 exercisable voting rights. The company's shares are listed on both Euronext Paris and Nasdaq under the ticker symbol NBTX.

Nanobiotix provided its Q3 2024 update, highlighting key operational progress. The company transferred US sponsorship of the global Phase 3 NANORAY-312 head and neck cancer study to Janssen, marking a important step toward potential NBTXR3 regulatory submission. The company reported €53.2 million in cash and cash equivalents as of September 30, 2024, with runway into Q4 2025.

Updates on NBTXR3 in pancreatic cancer and lung cancer studies with MD Anderson are expected in Q4 2024 and 1H 2025, respectively. The company strengthened its Supervisory Board with Dr. Margaret A. Liu and Ms. Anat Naschitz as board observers. An interim analysis for NANORAY-312 is anticipated after reaching required events and last patient recruitment in 1H 2026.

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announces participation in three major healthcare conferences in November 2024. The company will engage in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference (Nov 11, Boston), the Stifel Healthcare Conference (Nov 18, New York), and the Jefferies London Healthcare Conference (Nov 20, London). Company executives Laurent Levy (CEO) and Bart van Rhijn (CFO) will present at these events. All sessions will be webcast live and available for replay on the company's investor relations website.

Nanobiotix (NBTX), a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and share capital as of September 30, 2024. This disclosure is in compliance with French regulatory requirements. The company reported 47,426,851 shares outstanding, with 49,200,752 total theoretical voting rights and 49,178,634 total exercisable voting rights.

Nanobiotix, traded under the ticker NANO:FP on Bloomberg and NANO.PA on Reuters, is committed to regular updates on its capital structure. The company will publish new figures monthly if there are changes from previously disclosed information, adhering to transparency standards set by French financial authorities.